These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Gabryelewicz A J Physiol Pharmacol; 1996 Mar; 47(1):51-8. PubMed ID: 8777307 [TBL] [Abstract][Full Text] [Related]
43. Eczema responsive to treatment for Helicobacter pylori. Wilson WH Ann Allergy Asthma Immunol; 1995 Sep; 75(3):290. PubMed ID: 7552934 [No Abstract] [Full Text] [Related]
44. Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication. Treiber G; Walker S; Klotz U Arzneimittelforschung; 1997 Jan; 47(1):47-50. PubMed ID: 9037444 [TBL] [Abstract][Full Text] [Related]
45. [Importance of ranitidine in the eradication of Helicobacter pylori]. Beglinger C Rev Med Suisse Romande; 1995 Oct; 115(10):795-7. PubMed ID: 7501932 [No Abstract] [Full Text] [Related]
46. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction. Taskin V; Gurer I; Ozyilkan E; Sare M; Hilmioglu F Helicobacter; 2000 Mar; 5(1):38-40. PubMed ID: 10672050 [TBL] [Abstract][Full Text] [Related]
47. [Methods for increasing the efficacy and safety of Helicobacter pylori eradication regimens]. Zakharova NV Eksp Klin Gastroenterol; 2006; (4):59-66. PubMed ID: 17269426 [No Abstract] [Full Text] [Related]
49. Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita M; Tsuda M; Okita K; Sugiyama T; Nakazawa T Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S31-4. PubMed ID: 8574732 [TBL] [Abstract][Full Text] [Related]
50. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Asaka M; Kato M; Sugiyama T; Satoh K; Kuwayama H; Fukuda Y; Fujioka T; Takemoto T; Kimura K; Shimoyama T; Shimizu K; Kobayashi S; J Gastroenterol; 2003; 38(4):339-47. PubMed ID: 12743773 [TBL] [Abstract][Full Text] [Related]
52. [Intensifying the study of the proper treatment of digestive ulceration]. Yao X Zhonghua Nei Ke Za Zhi; 1997 Apr; 36(4):221-2. PubMed ID: 10374279 [No Abstract] [Full Text] [Related]
53. Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease. Tkach CL; Ariano RE Ann Pharmacother; 1998 Mar; 32(3):387. PubMed ID: 9533072 [No Abstract] [Full Text] [Related]
54. Barry Marshall, MD: H pylori 35 Years Later. Abbasi J JAMA; 2017 Apr; 317(14):1400-1402. PubMed ID: 28399250 [No Abstract] [Full Text] [Related]
55. Helicobacter pylori: a human pathogen. Murray L; Harvey I Lancet; 1995 Jun; 345(8964):1579-80. PubMed ID: 7791471 [No Abstract] [Full Text] [Related]
56. The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail. Shuter J; Fletcher DD; Simone VJ; Bellin EY J Urban Health; 1998 Dec; 75(4):896-902. PubMed ID: 9854250 [TBL] [Abstract][Full Text] [Related]